ABVXABIVAX Société Anonyme

HealthcareUSD
$116.50

The financials

ABIVAX Société Anonyme by the numbers

For the full year FY2025, revenue was €5.6M (−55% year on year) and net income −€336M.

ABIVAX Société Anonyme income statement, Q4 2025 against the same quarter a year earlier
Income statementQ4 2025Q4 2024Change
Revenuen/a€4.3Mn/a
Operating income−€72M−€43Mn/a
Net income−€82M−€39Mn/a
Diluted EPS−€1.02−€0.63n/a

Biotechnology

Ranks #132 of 145 by Smart Score

Compare peers
RYTM+0.66%
Rhythm Pharmaceuticals, Inc.
MIRM+2.0%
Mirum Pharmaceuticals, Inc.
SYRE+2.8%
Spyre Therapeutics, Inc.
PTCT+0.12%
PTC Therapeutics, Inc.
PCVX-0.35%
Vaxcyte, Inc.
IMVT+0.05%
Immunovant, Inc.